EU drug agency concludes that AstraZeneca benefits outweigh the risks
But agency says it cannot definitively rule out a like to blood clots
- Remains important to keep track of all side effects
- Will continue to study possible links to blood clots
This is not the definitive kind of 'this is safe' ruling we'd all like.